ALLMedicine™ IgA Nephropathy Center

Mar 14th, 2023 - We report the case of a 31-year-old male who presented with repeated episodes of nephritic-nephrotic syndrome in concomitance with infection. IgA was diagnosed and was initially responsive to treatment with immunosuppressors but further disease fl...

Mar 11th, 2023 - IgA nephropathy (IgAN) is a common primary glomerular disease, and supplementing qi dispelling wind and activating blood is commonly used as a treatment method in Chinese medicine. However, the existing studies have small sample sizes. This study ...

Mar 8th, 2023 - IgA nephropathy (IgAN), the most common form of primary glomerulonephritis, is mainly observed in young adults and children. Clinical and basic studies indicate the role of immunity in IgAN pathogenesis; however, corticosteroid therapy has been co...

Mar 8th, 2023 - Mitochondrial DNA (mtDNA) copy number (CN) is a biomarker of mitochondrial function and has been reported associated with kidney disease. However, its association with IgA nephropathy (IgAN), the most common cause of glomerulonephritis (GN), has n...

Mar 7th, 2023 - Introduction Numerous research have shown that serum Gal-deficient (Gd)-IgA1 levels are increased in IgA nephropathy (IgAN) patients and these levels are a dangerous risk factor for IgAN.It has been reported that a relationship between the gut mic...

Sep 27th, 2021 - A digest from evidence-based clinical practice guideline for IgA nephropathy 2020.|2021|Suzuki H,Kikuchi M,Koike K,Komatsu H,Matsuzaki K,|diagnosis,therapy,

Sep 25th, 2021 - The Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Management of Glomerular Diseases is an update to the KDIGO 2012 guideline. The aim is to assist clinicians caring for individuals with glomerulonephritis (G...

Apr 21st, 2016 - Evidence-based clinical practice guidelines for IgA nephropathy 2014.|2016|Yuzawa Y,Yamamoto R,Takahashi K,Katafuchi R,Tomita M,|diagnosis,etiology,therapy,

Mar 1st, 2023 - Approximately 320 patients with biopsy-proven IgAN will be randomized to receive 0.75 mg atrasentan or placebo daily for 132 weeks. Subjects receive a maximally tolerated and stable dose of a RAS (renin-angiotensin system) inhibitor [such as angio...

Feb 28th, 2023 - The investigators plan to randomize 60 participants with biopsy-proven IgAN to a YQF combined group (YQF compound combined with prednisolone, and cyclophosphamide if necessary) or an immunosuppression group (placebo-YQF combined with prednisolone,...

Feb 24th, 2023 - The goal of this clinical trial is to explore the effectiveness and safety of Telitacicept in adults with refractory IgA nephropathy. The main questions it aims to answer are: To evaluate the clinical efficacy of Telitacicept in patients with refr...

Feb 24th, 2023 - This is a Phase 3b, multicenter, open-label extension (OLE) study to evaluate the efficacy and safety of Nefecon treatment in patients with IgAN who have completed the Phase 3 Study Nef 301 and continue to be treated with a stable dose of RAS inhi...

Feb 23rd, 2023 - IgAN-microbiome is an investigator-initiated，multi-center，Observational study. This study will recruit IgA nephropathy patients who have not been treated with glucocorticoids and immunosuppressants for 6 months and have not taken antibiotics for...

Feb 21st, 2023 - The FDA granted accelerated approval to sparsentan (Filspari) for proteinuria in IgA nephropathy, Travere Therapeutics announced, marking the first non-immunosuppressive therapy for this rare condition. Also known as Berger's disease, proteinuria ...

Oct 25th, 2022 - Patients with immunoglobulin A (IgA) nephropathy showed clinically meaningful improvements in several measures of renal function after 9 months of treatment with a delayed-release formulation of the oral glucocorticoid budesonide, Nefecon, in a pi...

Jan 6th, 2022 - Patient survival in liver transplant recipients and graft survival in kidney transplant recipients was comparable among patients living with and without HIV, even 15 years later, researchers found in a retrospective study. For liver transplant rec...

Dec 16th, 2021 - The FDA granted accelerated approval for the first drug to reduce proteinuria in primary immunoglobulin A (IgA) nephropathy, the agency announced on Wednesday. The delayed released budesonide (Tarpeyo) capsules are indicated to lower increased pro...

Nov 24th, 2021 - Solid organ transplant recipients exhibited suboptimal immune responses to Pfizer's COVID-19 mRNA vaccine, even after four doses, a small French study found. All 37 patients examined had low neutralizing antibody titers and cellular responses, and...